ClinicalTrials.gg
RecruitingNCT06017713PPSTDCS-TOCUpdated Oct 23, 2026

tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder

An interventional study of tDCS + symptoms provocation in Obsessive-Compulsive Disorder, sponsored by Centre Hospitalier Henri Laborit. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Henri Laborit · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Obsessive-Compulsive Disorder with a site in France — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · France.

Planned enrollment
15th of 18
25 · median 45
Started
2023
the only one that year
No phase
14 of 20
5 open now
Registered
18th of 20
by date
Lead sponsor
4 of 20
Centre Hospitalier Henri Laborit

Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 18th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

5 of the 20 studies in Obsessive-Compulsive Disorder with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Obsessive-Compulsive Disorder with a site in France, or all of them as a file.
02

Study summary

This is a single-center study about patients with severe resistant OCD.

Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms.

After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel.

The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).

03

Conditions studied

  • Obsessive-Compulsive Disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient suffering from OCD evolving for at least 2 years diagnosed according to criteria;
  • Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale;
  • Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3);
  • Absence of epileptic pathology;
  • Chronic obsessive-compulsive disorder defined by a total YBOCS score > 20, or a subscale score > 15;
  • Drug-resistant obsessive-compulsive disorder despite treatment with:

    1. at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration
    2. and/or Behavioral and Cognitive therapy for at least 1 year;
  • Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study;
  • Patient aged between 18 and 70 included
  • Patient who has given his/her after having received written information on the planned procedure;
  • Patient benefiting from social security or by benefiting through a third party.

Exclusion criteria

Exclusion Criteria:

  • Woman of childbearing age without effective means of (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
  • Pregnant or nursing woman;
  • Patient hospitalized under duress (SPDT, SPDRE);
  • Patient under guardianship or curatorship;
  • Patient with another Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence).

Generalized anxiety disorder, social phobia, nicotine addiction and history of major depressive episodes are not exclusion criteria. Axis I comorbidity will be explored using MINI 5.0.0. ;

  • Patient suffering from a current depressive episode;
  • Patient at risk of suicide;
  • Patient with skin lesions on the scalp;
  • History of head trauma;
  • Patient with an intracerebral metal object
  • Patient with a pacemaker;
  • Presence of epileptic pathology;
  • Patient in an emergency situation or unable to give personal consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    tDCS + symptoms provocation

    Behavioral: tDCS + symptoms provocation

Interventions

  • BehavioraltDCS + symptoms provocation

    The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.

06

What researchers measure

Primary outcomes

  1. YBOCS scale

    The primary endpoint corresponds to the change in the score on the YBOCS scale between the inclusion visit (Day 0) and the Day 42 visit. A score of 0 corresponds to the absence of OCD and a score of 40 to maximum severity.

    Time frame: 3,5 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2027, 42 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 42 months is close to that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details, site details and index terms
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06017713
Lead sponsor
Centre Hospitalier Henri Laborit
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Oct 17, 2023
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Ghina HARIKA-GERMANEAU, Dr
Contact
ghina.harika-germaneau@ch-poitiers.fr
516526118 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion